-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqISIN US30049G1040-
Evoke Pharma IncBörse NasdaqISIN US30049G1040 WKN: A1W6DPSymbol EVOK
-
EVOKE PHARMA INCBörse Börse MünchenEURSymbol EV00
-
EVOKE PHARMA INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol EV00
-
EVOKE PHARMA INCBörse Börse FrankfurtEURSymbol EV00
-
EVOKE PHARMA INCBörse Gettex System der Börse MünchenEURSymbol EV00
-
EVOKE PHARMA INCBörse Quotrix System der Börse DüsseldorfEURSymbol EV00
-
EVOKE PHARMA INCBörse Börse DüsseldorfEURSymbol EV00
-
EVOKE PHARMA INCBörse Börse StuttgartEURSymbol EV00
-
EVOKE PHARMA INCBörse Börse BerlinEURSymbol EV00
-
EVOKE PHARMA INCBörse Gettex System der Börse MünchenEURSymbol EV0
-
EVOKE PHARMA INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol EV0
-
EVOKE PHARMA INCBörse Börse StuttgartEURSymbol EV0
-
EVOKE PHARMA INCBörse Quotrix System der Börse DüsseldorfEURSymbol EV0
-
EVOKE PHARMA INCBörse Börse DüsseldorfEURSymbol EV0
-
ISIN US30049G1040 WKN: A1W6DPUSDSymbol EVOK
-
ISIN US30049G1040 WKN: A1W6DPUSDSymbol EVOK
-
EURSymbol EV0
-
EURSymbol EV0
-
EURSymbol EV0
-
ISIN US30049G1040
WKN A1W6DP
Symbol EVOK
Börse
Nasdaq Zeitzone: Europe/Berlin
Firmenname
Evoke Pharma, Inc
Marktkapitalisierung
62.300.544 (+- 49%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
92.601.088 oder 32.000.000
Mitarbeiter
5 (+- 11%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
5 oder 4 Mitarbeiter
EBITDA 0
PEGRatio -0.1
Buchwert 0.119
Evoke Pharma underperformed den DAX um -159 % vom 05.11.2013 bis 15.10.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 1,5 USD -3,22%
Portrait der Aktie: Evoke Pharma
Das Unternehmen Evoke Pharma, Inc aus USA beschäftigt 5 Mitarbeiter.
Die Evoke Pharma Aktie konnte seit dem 05.11.2013 leider keine Rendite erwirtschaften. Die Kursverluste lagen bei -88%.
Dir gefallen die Informationen zu Evoke Pharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Evoke Pharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Evoke Pharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Evoke Pharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
10 News & Informationen zur Evoke Pharma Aktie
Evoke Pharma To Report Second Quarter 2021 Financial Results On August 12, 2021
SOLANA BEACH, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for
Evoke Pharma Launches Gimoti® Patient And Physician Experience Program
SOLANA BEACH, Calif., July 14, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal
Evoke Pharma, EVERSANA And The International Foundation For Gastrointestinal Disorders Announce Membership Into IFFGD's Industry Council
SOLANA BEACH, Calif., CHICAGO, and MOUNT PLEASANT, S.C., June 29, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. EVOK, a specialty pharmaceutical company focused
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ja…
Evoke Pharma Announces Pricing of Public Offering of Common Stock
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be $12.5 million. Evoke has granted the underwriter a 45-day option to purchase up to 750,000 additional shares of its common stock. The offering is expected to close on or about January 19, 2021, subject to satisfaction of customary closing conditions. Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering.Evoke intends to use the net proceeds from the offering for working capital and general corporate purposes, including funding commercialization activities, research and development activities, clinical trial expenditures, and possible acquisition of new technologies or products.The offering is being conducted pursuant to a shelf registration statement (File No. 333-251614) previously filed and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC and will be available free of charge on the website of the SEC at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Laidlaw & Company (UK) Ltd, Attention: Syndicate Department, 521 Fifth Avenue, New York, NY 10175, by telephone at (212) 953-4917 or by email at syndicate@laidlawltd.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.About Evoke Pharma, Inc.Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.Safe Harbor Statement Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Evoke’s current beliefs and expectations. These forward-looking statements include statements regarding Evoke’s expectations on the completion, timing and size of the offering and the anticipated use of proceeds therefrom. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties inherent in Evoke’s business, including those described in Evoke’s periodic filings with the SEC and the prospectus supplement and related prospectus for this offering filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Investor Contact: The Ruth Group Jan Medina, CFA Tel: 646-536-7035 jmedina@theruthgroup.comMedia Contact: The Ruth Group Annika Parrish Tel: 720-412-9042 aparrish@theruthgroup.com
Evoke Pharma Announces Pricing of Public Offering of Common Stock
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for …
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Organogenesis Holdings (NASDAQ:ORGO) stock rose 28.47% to $9.43 during Wednesday's after-market session. Organogenesis Holdings's trading …
Evoke Pharma under pressure on proposed public offering (NASDAQ:EVOK)
Evoke Pharma Announces Proposed Public Offering of Common Stock
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for …
Evoke Pharma shares surge on positive findings from Gimoti market research study (NASDAQ:EVOK)